Genitourinary fungal infections: A therapeutic conundrum

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 8, 2001, Pages 1211-1226

  Wise, G J ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Fungal infection; Genitourinary; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; CASPOFUNGIN; CLOTRIMAZOLE; CORTICOSTEROID; DEFEROXAMINE; ECONAZOLE; FLUCONAZOLE; FLUCYTOSINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIDAZOLE; ITRACONAZOLE; KETOCONAZOLE; MACROPHAGE ACTIVATING FACTOR; MICONAZOLE; POSACONAZOLE; RAVUCONAZOLE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRIAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ADULT; AGED; ANEMIA; ASPERGILLOSIS; ASPERGILLUS; AWARENESS; BACTERIAL COLONIZATION; BLASTOMYCES; BLASTOMYCOSIS; CANDIDA; CANDIDIASIS; CHILD; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; COCCIDIOIDES; COCCIDIOIDOMYCOSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; CRYPTOCOCCUS; DEATH; DEBRIDEMENT; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; DRUG SYNTHESIS; ENTEROCOLITIS; FEMALE; FEVER; FUNGUS; HEADACHE; HISTOPLASMA; HISTOPLASMOSIS; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOCALCEMIA; HYSTERECTOMY; IMAGING; IMMUNE DEFICIENCY; INFANT; MALE; MUCORMYCOSIS; MULTICENTER STUDY; NAUSEA AND VOMITING; NEPHRECTOMY; NEPHROSTOMY; NEPHROTOXICITY; ORCHIECTOMY; ORGAN TRANSPLANTATION; PAIN; PATHOGENESIS; PHLEBITIS; PREMATURITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; SPECIES DIFFERENCE; STAPHYLOCOCCUS SAPROPHYTICUS; THROMBOCYTOPENIA; UREMIA; UROGENITAL TRACT INFECTION;

ANIMALS; ANTIFUNGAL AGENTS; FEMALE UROGENITAL DISEASES; HUMANS; MALE UROGENITAL DISEASES; MYCOSES; OPPORTUNISTIC INFECTIONS;

EID: 0034875863     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.8.1211     Document Type: Review

References (143)

1. Emerging infections: Microbial threats to health in the United States
2. The emerging fungal threat
3. Nosocomial bloodstream infections in United States Hospitals: A three year analysis
4. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System
5. Invasive candida infections. Evolution of a fungal pathogen
6. Changing patterns in genitourinary fungal infections
7. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990
8. The prevalence of nosocomial infection in intensive care units in Europe
9. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: Results of population-based laboratory active surveillance
10. Documented fungal infections after prophylaxis or therapy with wide spectrum antibiotics: Relationship between certain fungal pathogens and particular antimicrobials
11. Blastomycosis
12. Blastomycosis acquired occupationally during prairie dog relocation-Colorado, 1998
13. Epidemiological and clinical features of pulmonary blastomycosis
14. Blastomycosis in the immunocompromised patient
15. Blastomycosis of the epididymis and prostate
16. Female genital blastomycosis. Case report and review
17. Diagnosis of blastomycosis
18. Therapy of blastomycosis
19. Coccidiodomycosis in New York State
20. Coccidiodomycosis
21. Coccidiodomycosis
22. Bilateral isolated adrenal coccioidomycosis
23. Genitourinary coccidioidomycosis
24. Coccidioidomycosis of the female genital tract
25. Markers of coccidioidomycosis before cardiac or renal transplantation and risk of recurrent infection
26. Histoplasmosis - Kentucky
27. Effect of successful treatment with amphotericin B on Histoplasma capsulatum variety capsulatum polysaccharide antigen levels in patients with AIDS and histoplasmosis
28. Histoplasmosis of kidneys presenting as chronic recurrent renal disease
29. Transmission of Histoplasma Capsulatum by organ transplantation
30. Conjugal histoplasmosis: A consequence of progressive dissemination in the index case after steroid therapy
31. Comparison of radioimmunoassay and enzyme-linked immunoassay methods for detection of Histoplasma capsulatum var. capsulatum antigen
32. Diagnosis of histoplasmosis by antigen detection during an outbreak in Indianapolis, Ind
33. Pharmacotherapy of disseminated histoplasmosis in patients with AIDS
34. Itraconazole maintenance therapy for histoplasmosis in AIDS: A prospective, multicenter study
35. Fluconazole therapy for histoplasmosis
36. Fungal infections: A growing threat
37. Fungal infections of the Urinary Tract
38. Invasive aspergillosis
39. Association between incidence of aspergillus antigenemia and exposure to construction works at a hospital site
40. Renal aspergillosis and AIDS
41. Renal aspergilloma in AIDS
42. Isolated kidney localization of invasive aspergillosis in a patient with AIDS
43. Prostatic and epididymo-orchitis due to Aspergillus fumigatus in a patient with AIDS
44. Prostatic aspergillosis
45. Pathogenesis, immunobiology and epidemiology of cryptococcosis
46. Fungaemia in hospitalized patients
47. Adrenal insufficiency due to cryptococcosis
48. Cryptococcal pyelonephritis in a renal transplant recipient
49. Prostatic sequestration of Cryptococcus neoformans in immunocompromised persons treated for cryptococcal meningoencephalitis
50. Comparison of two rapid latex agglutination tests for detection of cryptococcal capsular polysaccharide
51. Efficacy of a short-term amphotericin B + flucytosine combination therapy followed by itraconazole monotherapy in acute and chronic AIDS-associated cryptococcosis
52. Persistence of Cryptococcus neoformans in seminal fluid and urine under itraconazole treatment. The urogenital tract (prostate) as a niche for Cryptococcus neoformans
53. AIDS and the urologist
54. Rhizopus microsporus in wooden tongue depressors: A major threat or minor inconvenience?
55. Mucormycosis (zygomycosis): Is there news for the clinician?
56. Cerebral mucormycosis associated with intravenous drug use: Three case reports and
57. Mucormycosis of the genitourinary tract
58. Mucormycosis of the graft in a renal transplant recipient
59. Mucor pyelonephritis. Report of a case diagnosed by urine cytology, with diagnostic considerations in the workup of funguria
60. Successful medical management of isolated renal zygomycosis: Case report and review
61. Disseminated zygomycosis in a neutropenic patient: Successful treatment with amphotericin B lipid complex and granulocytic-stimulating factor
62. Phycomycosis of the vulva
63. Trends and sources of nosocomial fungemia
64. Prospective multicenter surveillance study of funguria in hospitalized patients
65. Early detection of candiduria by polymerase chain reaction in high risk patients
66. Fungal urinary tract infections in patients at risk
67. Quantitative urine cultures do not reliably detect renal candidiasis in rabbits
68. Serodiagnosis of candidiasis, aspergillosis, and cryptococcosis
69. Immune response in patients with persistent candiduria and occult candidemia
70. Fungal bezoar causing ureteric obstruction
71. Unusual case of renal candida fungus balls
72. An unusual cause of acute renal failure: Bilateral ureteral obstruction due to Candida tropicalis fungus balls
73. Percutaneous nephrostomy for non-operative management of fungal urinary tract infections
74. Emphysematous pyelonephritis caused by Candida albicans
75. Yeast perinephric abscess: Report of a case and review
76. True mycotic arteritis by Candida albicans in 2 kidney transplant recipients from the same donor
77. Candida albicans cystitis: Report of a case with special emphasis on diagnosis and treatment
78. Candida albicans "fungus ball" in bladder
79. Cystitis emphysematous caused by Candida albicans
80. Fungal infections of the perivesical space
81. Emphysematous prostatitis and cystitis secondary to Candida albicans
82. Prostatic abscess due to Candida tropicalis in a non-acquired immunodeficiency syndrome patient
83. Prostatic abscess due to Candida albicans
84. Isolated candidal prostatitis
85. Taxonomic and nomenclature evaluation of the genera Candida and
86. The changing face of candidemia; emergence of non-Candida albicans species and anti-fungal resistance
87. Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans
88. Torulopsis glabrata urinary infections: A review
89. Torulopsis glabrata fungal cystitis
90. Systemic candidiasis presenting with prostatic abscess
91. A rare cause of epididymorchitis
92. Torulopsis glabrata pelvic abscess and septicemia
93. Yeast perinephric abscess: Report of a case and review
94. Renal abscess and fungemia due to Torulopsis glabrata. Successful treatment with drainage and fluconazole
95. The management of obstructive renal candidiasis in the neonate
96. Candida lusitaniae infection in the newborn: Case report and review of the literature
97. Risk factors for candidemia in a children's hospital
98. The role of percutaneous nephrostomy in the management of obstructing candidiasis of the urinary tract in infants
99. Urinary tract candidiasis in neonates and infants
100. Diagnosis and management of obstructive renal candidiasis in the neonate
101. Treatment of candiduria with liposomal amphotericin B (L-ampB-LRC) in children
102. Prospective study fluconazole therapy in systemic neonatal fungal infection
103. A prospective multicenter surveillance study of funguria in hospitalized patients
104. The enigma of candiduria: Evolution of bladder irrigation with amphotericin B for management-From anecdote to dogma and a lesson from Machiavelli
105. Bladder irrigation with amphotericin B for treatment of fungal urinary tract infections
106. Candiduria: A randomized, double-blind study of treatment with fluconazole and placebo
107. Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria
108. Yeast in the urine: Solutions for a budding problem
109. Failure of a lipid amphotercin B preparation to eradicate candiduria: Preliminary findings based on three cases
110. Candida infections in surgical patients. Dose requirements and toxicity of amphotericin B
111. Therapeutic approaches in patients with candidemia
112. Percutaneous identification and removal of fungus ball from renal pelvis
113. Strategies in the treatment of systemic fungal infections
114. Oral azole drugs as systemic antifungal therapy
115. Antifungal therapy during pregnancy
116. upon switching lipid-containing amphotericin B formulations
117. Liposomal amphotericin B: An effective nontoxic preparation for the treatment of urinary tract infections caused by Candida albicans
118. Do the imidazoles have a role in the management of genitourinary fungal infections?
119. Congenital malformations in an infant born to a woman treated with fluconazole
120. Pharmacological treatment of genitourinary fungal infections
121. The potential role of cytokine therapy for fungal infections in patients with cancer: Is recovery from neutropenia all that is Clin. needed?
122. Role of granulocyte-macrophage colony stimulating factor as adjuvant therapy for fungal infections in patients with cancer
123. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness
124. Burden of Aspergillosis-related hospitalizations in the United States
125. Myelofibrosis complicated by infection due to Candida albicans: Emergence of resistance to antifungal agents during therapy
126. Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans
127. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles
128. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole
129. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
130. Fluconazole-resistant Candida parapsilosis fungemia in a patient with AIDS
131. Infection due to fluconazole-resistant Candida in patients with AIDS: Prevalence and microbiology
132. Fluconazole and the changing epidemiology of candidemia
133. Letters to the Editor: Re: Fluconazole treatment in Torulopsis glabrata upper urinary tract infection causing ureteral obstruction
134. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
135. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance
136. Editorial response: The contribution of fluconazole to the changing epidemiology of invasive candidal infections
137. Novel triazole antifungal agents
138. First drug in new class of antifungals approved
139. Cytokines for opportunistic fungal infections
140. Increasing rates of hospitalization due to septicemia in the US elderly population. 1986-1997
141. Fever in immunocompromised patients
142. Management of persistent fever in the neutropenic patient